Skip to main content

01-09-2023 | Semaglutide | News


FDA approves high-dose semaglutide for adolescents with obesity

Author: Lynda Williams


medwireNews: The US FDA has granted approval for the use of semaglutide at a dose of 2.4 mg/week for the treatment of obesity in children aged 12 years or older with a BMI in the 95th percentile or higher for their age and sex.

The announcement follows findings from the STEP TEENS trial which demonstrated substantial weight loss with the glucagon-like peptide-1 receptor agonist compared with placebo.

Semaglutide 2.4 mg has previously been approved for use in adults with a BMI above 30 kg/m2 and those with a BMI above 27 kg/m2 and a weight-related comorbidity, such as type 2 diabetes or hypertension.

The agent carries a black box warning against its use in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2023 Springer Healthcare Ltd, part of the Springer Nature Group


Novel clinical evidence in continuous glucose monitoring

Novel clinical evidence in continuous glucose monitoring

How real-world studies complement randomized controlled trials

Jean-Pierre Riveline uses data from real-life continuous glucose monitoring studies to illustrate how these can uncover critical information about clinical outcomes that are hard to assess in randomized controlled trials.

This video has been developed through unrestricted educational funding from Abbott Diabetes Care.

Watch the video